Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Sarcoma 9Ovarian Neoplasms 6Neoplasms 6Liposarcoma 4Neoplasm Metastasis 3Leiomyosarcoma 3Breast Neoplasms 3Neoplasms by Site 2Uterine Neoplasms 1Skin Diseases 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms, Connective and Soft Tissue 1Neoplasms by Histologic Type 1Mesothelioma, Malignant 1Liver Diseases 1Liposarcoma, Myxoid 1Hepatic Insufficiency 1Genital Diseases, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Endocrine Gland Neoplasms 1Carcinoma 1Breast Diseases 1Adnexal Diseases 1

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × Trabectedin × Clear all
NCT00027508 2015-02-24

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

PharmaMar

Phase 2 Terminated
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡